Table 1.
Results of base-case analysis
| Base-case analysis | Best supportive care | Lenalidomide | Net change |
|---|---|---|---|
| Costs (discounted) [£] | |||
| Cost of treatment (drug treatment and transfusions) | 2243 | 43,359 | 41,116 |
| Adverse events associated with treatment | 0 | 184 | 184 |
| Cost of iron chelation | 45,753 | 31,440 | − 14,313 |
| Cost of transfusion and chelation complications | 958 | 956 | − 2 |
| Cost of blood transfusion | 61,083 | 49,413 | − 11,669 |
| Cost of AML | 3871 | 4558 | 688 |
| General monitoring costs | 84 | 4553 | 4469 |
| Monitoring cost with standard care | 9208 | 6977 | − 2230 |
| Monitoring cost for iron chelation | 43 | 29 | − 13 |
| Total cost | 123,241 | 141,470 | 18,229 |
| Life-years (undiscounted) | |||
| TI | 0.15 | 1.72 | 1.57 |
| TD—no chelation | 0.13 | 0.26 | 0.13 |
| TD—chelation | 3.00 | 2.17 | − 0.83 |
| TD—chelation failure | 1.66 | 1.61 | − 0.04 |
| AML | 0.24 | 0.29 | 0.05 |
| Total life-years | 5.17 | 6.06 | 0.88 |
| QALYs (discounted) | |||
| TI | 0.12 | 1.35 | 1.23 |
| TD—no chelation | 0.08 | 0.16 | 0.08 |
| TD—chelation | 1.70 | 1.16 | − 0.54 |
| TD—chelation failure | 0.92 | 0.85 | − 0.07 |
| AML | 0.13 | 0.15 | 0.02 |
| Total QALYs | 2.95 | 3.67 | 0.72 |
| Incremental cost-effectiveness ratios | |||
| Cost per life-year gained | £20,639 | ||
| Cost per QALY gained | £25,310 | ||
AML acute myeloid leukaemia, QALY quality-adjusted life year, TD transfusion dependent, TI transfusion independent